The role of medical structural genomics in discovering new drugs for infectious diseases

PLoS Computational Biology

Volumn 5, Issue 10, 2009, Pages

  Van Voorhis, Wesley C ^a   Hol, Wim G J ^b   Myler, Peter J ^b,c   Stewart, Lance J ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d DeCODE Chemistry & Biostructures   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFECTIOUS DISEASE; STRUCTURAL GENOMICS;

ADENOSINE DEAMINASE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BACTERIAL ENZYME; BACTERIAL PROTEIN; BACTERIAL TOXIN; BLOOD CLOTTING FACTOR 10A; CALCINEURIN; CHOLERA TOXIN; COAT PROTEIN; CYCLOPHILIN; NEW DRUG; PEPTIDE DEFORMYLASE; PHOSPHOTRANSFERASE; PORPHOBILINOGEN SYNTHASE; PROTEINASE; RENIN; SIALIDASE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN 41; VIRUS PROTEIN; ANTIINFECTIVE AGENT;

BINDING AFFINITY; CHEMICAL STRUCTURE; CRYOPROTECTION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; FLUORESCENCE POLARIZATION; HIGH THROUGHPUT SCREENING; HOST PATHOGEN INTERACTION; HYDROGEN BOND; INFECTION; MACROMOLECULE; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMODIUM FALCIPARUM; PROTEIN ASSEMBLY; PROTEIN DATA BANK; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; STRUCTURAL GENOMICS; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMICAL MODEL; CHEMISTRY; COMMUNICABLE DISEASE; GENETICS; GENOMICS; HUMAN; METHODOLOGY; PHARMACOGENETICS; PROTEIN DATABASE; SYSTEMS BIOLOGY;

ANIMALS; ANTI-INFECTIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; COMMUNICABLE DISEASES; DATABASES, PROTEIN; DRUG DESIGN; GENOMICS; HUMANS; MODELS, CHEMICAL; MODELS, MOLECULAR; PHARMACOGENETICS; SYSTEMS BIOLOGY;

EID: 70350479575     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000530     Document Type: Review

References (69)

1. Payne DJ , Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
2. Haquin S, Oeuillet E, Pajon A, Harris M, Jones AT, et al. (2008) Data management in structural genomics: An overview. Methods Mol Biol 426: 49-79.
3. Wright HT, Reynolds KA (2007) Antibacterial targets in fatty acid biosynthesis. Curr Opin Microbiol 10: 447-453.
4. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, et al. (2009) Type II fatty acid synthesis is not a suitable antibiotic target for gram-positive pathogens. Nature 458: 83-86.
5. Hoon S, Smith AM, Wallace IM, Suresh S, Miranda M, et al. (2008) An integrated platform of genomic assays reveals small-molecule bioactivities. Nat Chem Biol 4: 498-506.
6. Ericsson UB, Hallberg BM, Detitta GT, Dekker N, Nordlund P (2006) Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal Biochem 357: 289-298.
7. Congreve M, Chessari G, Tisi D, Woodhead AJ (2008) Recent developments in fragment-based drug discovery. J Med Chem 51: 3661-3689.
8. Verlinde CLMJ, Kim H, Bernstein BE, Mande SC, Hol WG (1997) Antitrypanosomiasis drug development based on structures of glycolytic enzymes. In: Veerapandian P, ed. Structurebased drug design. New York: Marcel Dekker. pp 365-394.
9. Rees DC, Congreve M, Murray CW, Carr R (2004) Fragment-based lead discovery. Nat Rev Drug Discov 3: 660-672.
10. Congreve M, Carr R, Murray C, Jhoti H (2003) A "rule of three" for fragment-based lead discovery? Drug Discov Today 8: 876-877.
11. Nienaber VL, Greer J (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nature Biotechnol 18: 1105-1108.
12. Neumann T, Junker HD, Schmidt K, Sekul R (2007) SPR-based fragment screening: Advantages and applications. Curr Top Med Chem 7: 1630-1642.
13. Jhoti H, Cleasby A, Verdonk M, Williams G (2007) Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 11: 485-493.
14. Erlanson DA (2006) Fragment-based lead discovery: A chemical update. Curr Opin Biotechnol 17: 643-652.
15. Bosch J, Robien MA, Mehlin C, Boni E, Riechers A, et al. (2006) Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J Med Chem 49: 5939-5946.
16. Davies DR, Mamat B, Magnusson OT, Christensen J, Haraldsson MH, et al. (2009) Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J Med Chem 52: 4694-4715.
17. Liuzzi M, Deziel R, Moss N, Beaulieu P, Bonneau AM, et al. (1994) A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372: 695-698.
18. Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009.
19. Kankare J, Salminen T, Lahti R, Cooperman BS, Baykov AA, et al. (1996) Structure of Escherichia coli inorganic pyrophosphatase at 2.2 Å resolution. Acta Crystallogr D Biol Crystallogr 52: 551-563.
20. Oksanen E, Ahonen AK, Tuominen H, Tuominen V, Lahti R, et al. (2007) A complete structural description of the catalytic cycle of yeast pyrophosphatase. Biochemistry 46: 1228-1239.
21. Sivula T, Salminen A, Parfenyev AN, Pohjanjoki P, Goldman A, et al. (1999) Evolutionary aspects of inorganic pyrophosphatase. FEBS Lett 454: 75-80.
22. Lawrence SH, Ramirez UD, Tang L, Fazliyez F, Kundrat L, et al. (2008) Shape shifting leads to small-molecule allosteric drug discovery. Chem Biol 15: 586-596.
23. Berman H, Henrick K, Nakamura H, Markley JL (2007) The worldwide Protein Data Bank (wwPDB): Ensuring a single, uniform archive of PDB data. Nucleic Acids Res 35: D301-303.
24. Edwards AM, Bountra C, Kerr DJ, Willson TM (2009) Open access chemical and clinical probes to support drug discovery. Nat Chem Biol 5: 436-440.
25. Choi KH, Groarke JM, Young DC, Rossmann MG, Pevear DC, et al. (2004) Design, expression, and purification of a Flaviviridae polymerase using a high-throughput approach to facilitate crystal structure determination. Protein Sci 13: 2685-2692.
26. Graslund S, Sagemark J, Berglund H, Dahlgren LG, Flores A, et al. (2008) The use of systematic N- and C-terminal deletions to promote production and structural studies of recombinant proteins. Protein Expr Purif 58: 210-221.
27. Luft JR, Collins RJ, Fehrman NA, Lauricella AM, Veatch CK, et al. (2003) A deliberate approach to screening for initial crystallization conditions of biological macromolecules. J Struct Biol 142: 170-179.
28. Santarsiero BDYD, Lee CC, Spraggon G, Gu J, ScheibeD, Uber EC, Cornell EW, Nordmeyer RA, Kolbe WF, Jin J, Jones AL, Jaklevic JM, Schultz PG, Stevens RC (2002) An approach to rapid protein crystallization using nanodroplets. J Appl Crystallogr 35: 278-281.
29. Hansen CL, Skordalakes E, Berger JM, Quake SR (2002) A robust and scalable microfluidic metering method that allows protein crystal growth by free interface diffusion. Proc Natl Acad Sci U S A 99: 16531-16536.
30. Zheng B, Roach LS, Ismagilov RF (2003) Screening of protein crystallization conditions on a microfluidic chip using nanoliter-size droplets. J Am Chem Soc 125: 11170-11171.
31. Gerdts CJ, Elliott M, Lovell S, Mixon MB, Napuli AJ, et al. (2008) The plug-based nanovolume Microcapillary Protein Crystallization System (MPCS). Acta Crystallogr D Biol Crystallogr 64: 1116-1122.
32. Wilson J (2002) Towards the automated evaluation of crystallization trials. Acta CrystallogrDBiol Crystallogr 58: 1907-1914.
33. Pan S, Shavit G, Penas-Centeno M, Xu DH, Shapiro L, et al. (2006) Automated classification of protein crystallization images using support vector machines with scale-invariant texture and Gabor features. Acta Crystallogr D Biol Crystallogr 62: 271-279.
34. Liu R, Freund Y, Spraggon G (2008) Imagebased crystal detection: A machine-learning approach. Acta Crystallogr D Biol Crystallogr 64: 1187-1195.
35. Fan E, Baker D, Fields S, Gelb MH, Buckner FS, et al. (2008) Structural genomics of pathogenic protozoa: An overview. Methods Mol Biol 426: 497-513.
36. Wagner A, Diez J, Schulze-Briese C, SchluckebierG (2009) Crystal structure of ultralente - A microcrystalline insulin suspension. Proteins 74: 1018-1027.
37. Thorne RESZ, Kmetko J, O'Niell J, Gillilan R (2003) Microfabricated mounts for high-throughput macromolecular cryocrystallography. J Applied Crystallography 36: 1455-1460.
38. Schorlemmer HU, Bosslet K, Dickneite G, Luben G, Sedlacek HH (1984) Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems. Behring Inst Mitt: 157-173.
39. Costantino L, Barlocco D (2006) Privileged structures as leads in medicinal chemistry. Curr Med Chem 13: 65-85.
40. Biros SM, Moisan L, Mann E, Carella A, Zhai D, et al. (2007) Heterocyclic alpha-helix mimetics for targeting protein-protein interactions. Bioorg Med Chem Lett 17: 4641-4645.
41. Robinson JA (2008) Beta-hairpin peptidomimetics: design, structures and biological activities. Acc Chem Res 41: 1278-1288.
42. Saraogi I, Hamilton AD (2008) alpha-Helix mimetics as inhibitors of protein-protein interactions. Biochem Soc Trans 36: 1414-1417.
43. Root MJ, Steger HK (2004) HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 10: 1805-1825.
44. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
45. Ferrer M, Kapoor TM, Strassmaier T, Weissenhorn W, Skehel JJ, et al. (1999) Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 6: 953-960.
46. Lapatto R, Blundell T, Hemmings A, Overington J, Wilderspin A, et al. (1989) X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 342: 299-302.
47. Miller M, Schneider J, Sathyanarayana BK, Toth MV, Marshall GR, et al. (1989) Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution. Science 246: 1149-1152.
48. Navia MA, Fitzgerald PM, McKeever BM, Leu CT, Heimbach JC, et al. (1989) Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337: 615-620.
49. Wlodawer A, Miller M, Jaskolski M, Sathyanarayana BK, Baldwin E, et al. (1989) Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease. Science 245: 616-621.
50. Wlodawer A, Vondrasek J (1998) Inhibitors of HIV-1 protease: A major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct 27: 249-284.
51. Abdel-Rahman HM, Al-karamany GS, El-Koussi NA, Youssef AF, Kiso Y (2002) HIV protease inhibitors: Peptidomimetic drugs and future perspectives. Curr Med Chem 9: 1905-1922.
52. Chrusciel RA, Strohbach JW (2004) Non-peptidic HIV protease inhibitors. Curr Top Med Chem 4: 1097-1114.
53. Das K, Lewi PJ, Hughes SH, Arnold E (2005) Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 88: 209-231.
54. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256: 1783-1790.
55. Smerdon SJ, Jager J, Wang J, Kohlstaedt LA, Chirino AJ, et al. (1994) Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 91: 3911-3915.
56. Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, et al. (2000) BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuramini-dase inhibitor through structure-based drug design. J Med Chem 43: 3482-3486.
57. Bossart-Whitaker P, Carson M, Babu YS, Smith CD, Laver WG, et al. (1993) Threedimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J Mol Biol 232: 1069-1083.
58. Kim CU, Lew W, Williams MA, Liu H, Zhang L, et al. (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119: 681-690.
59. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363: 418-423.
60. Hadfield AT, Lee W, Zhao R, Oliveira MA, Minor I, et al. (1997) The refined structure of human rhinovirus 16 at 2.15 Å resolution: Implications for the viral life cycle. Structure 5: 427-441.
61. Merritt EA, Zhang Z, Pickens JC, Ahn M, Hol WG, et al. (2002) Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin. J Am Chem Soc 124: 8818-8824.
62. Hu X, Nguyen KT, Jiang VC, Lofland D, Moser HE, et al. (2004) Macrocyclic inhibitors for peptide deformylase: A structure-activity relationship study of the ring size. J Med Chem 47: 4941-4949.
63. Aronov AM, Verlinde CL, Hol WG, Gelb MH (1998) Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design. J Med Chem 41: 4790-4799.
64. Bressi JC, Choe J, Hough MT, Buckner FS, Van Voorhis WC, et al. (2000) Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: Elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine. J Med Chem 43: 4135-4150.
65. Jin L, Harrison SC (2002) Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci U S A 99: 13522-13526.
66. Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, et al. (2000) Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol 7: 493-504.
67. Lam PY, Clark CG, Li R, Pinto DJ, Orwat MJ, et al. (2003) Structure-based design of novel guanidine/benzamidine mimics: Potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. J Med Chem 46: 4405-4418.
68. Terasaka T, Kinoshita T, Kuno M, Seki N, Tanaka K, et al. (2004) Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors. J Med Chem 47: 3730-3743.
69. Noble ME, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: Insights into drug design from structure. Science 303: 1800-1805.